What is the simulated dosing for a certain drug? MTD(maximum tolerated dosing) or metronomic?

Our models don't differentiate between different types of dosing, so they can be viewed as outcomes for standard clinical practice. For instance, if MTD is more common in practice, the models may more closely reflect MTD.

Other Questions

Back to Help Center

Is there a way to cancel the order before it is processed if the patient decides they no longer want the ImpriMed test?

In order to cancel the order, please contact us by sending an email to support@imprimedicine.com.

How long until I get my ImpriMed report?

Our flow cytometry, PARR, and Immunoprofile reports are emailed to you 3-4 days after receipt of your patient’s sample(s) at our lab. The Personalized Prediction Profile reports are emailed to you 6-7 days after receipt of your patient’s sample(s) at our lab.

I put the media tubes into the freezer. Can I still use the media tubes?

No, We will send you another batch of media tubes you could use. Please email us at support@imprimedicine.com or request fresh tubes online via our Vet Portal.

What does flow cytometry tell me about my patient’s specimen?

ImpriMed’s flow cytometry report provides comprehensive information about the specimen’s immunophenotype. B-cell and T-cell immunophenotypes are useful in determining lymphoma/leukemia subtype and prognosis. In addition, our panel of ten antigens can also be used in the diagnosis of T-zonal lymphoma, acute leukemia, and other diseases. Antigens levels reported are: CD21, CD79a, CD3, CD4, CD8, CD5, CD45, CD34, CD14, and MHC class II. For more information, see: https://pubmed.ncbi.nlm.nih.gov/26953614/

What does PARR tell me about my patient’s specimen?

PARR, which stands for PCR for Antigen Receptor Rearrangements, is used to discriminate between lymphoma/leukemia and reactive/inflammatory conditions when cytology is equivocal. Our canine PARR assay detects the expansion of B-cell cancer clones by amplifying the VJ region of the immunoglobulin heavy chain gene (IgH) and detects the expansion of T-cell cancer clones by amplifying a region in the T-cell receptor gamma chain gene.